Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Bergman

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Journal of the American College of Cardiology|November 18, 2000
Physical training in Syndrome X: physical training counteracts deconditioning and pain in Syndrome XB E Eriksson, R Tyni-Lennè, J Svedenhag, et al.
Optics Letters|October 31, 2009
Saturable Bragg reflector self-starting passive mode locking of a Cr(4+):YAG laser pumped with a diode-pumped Nd:YVO(4) laserB C Collings, J B Stark, S Tsuda, et al.
Diabetes Care|September 6, 2023
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 TrialsJulio Rosenstock, Luis Vázquez, Stefano Del Prato, et al.
Lancet (London, England)|September 20, 2025
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trialTamara S Hannon, Lily C Chao, Margarita Barrientos-Pérez, et al.
Diabetes, Obesity & Metabolism|March 14, 2025
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programmeBrandon K Bergman, Julio Rosenstock, W Timothy Garvey, et al.
Diabetes Care|October 12, 2023
Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4Maciej T Małecki, Rachel L Batterham, Naveed Sattar, et al.
The New England Journal of Medicine|June 25, 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesJuan P Frías, Melanie J Davies, Julio Rosenstock, et al.
Diabetes Care|April 19, 2024
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial ProgramPhilip Zeitler, Rodolfo J Galindo, Melanie J Davies, et al.
Dimensions of Critical Care Nursing : DCCN|November 15, 2011
Using variance tracking to improve outcomes and reduce costsL M Benson, J Bowes, K Cheesebro, et al.
Vaccine|January 5, 2000
Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicityD A Dilts, I Riesenfeld-Orn, J P Fulginiti, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Journal of the American College of Cardiology|November 18, 2000
Physical training in Syndrome X: physical training counteracts deconditioning and pain in Syndrome XB E Eriksson, R Tyni-Lennè, J Svedenhag, et al.
Optics Letters|October 31, 2009
Saturable Bragg reflector self-starting passive mode locking of a Cr(4+):YAG laser pumped with a diode-pumped Nd:YVO(4) laserB C Collings, J B Stark, S Tsuda, et al.
Diabetes Care|September 6, 2023
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 TrialsJulio Rosenstock, Luis Vázquez, Stefano Del Prato, et al.
Lancet (London, England)|September 20, 2025
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trialTamara S Hannon, Lily C Chao, Margarita Barrientos-Pérez, et al.
Diabetes, Obesity & Metabolism|March 14, 2025
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programmeBrandon K Bergman, Julio Rosenstock, W Timothy Garvey, et al.
Diabetes Care|October 12, 2023
Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4Maciej T Małecki, Rachel L Batterham, Naveed Sattar, et al.
The New England Journal of Medicine|June 25, 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesJuan P Frías, Melanie J Davies, Julio Rosenstock, et al.
Diabetes Care|April 19, 2024
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial ProgramPhilip Zeitler, Rodolfo J Galindo, Melanie J Davies, et al.
Dimensions of Critical Care Nursing : DCCN|November 15, 2011
Using variance tracking to improve outcomes and reduce costsL M Benson, J Bowes, K Cheesebro, et al.
Vaccine|January 5, 2000
Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicityD A Dilts, I Riesenfeld-Orn, J P Fulginiti, et al.
Pageof 14